A 3-year study of 200,000 Cigna customers has revealed just how expensive correctable health conditions can be and not knowing what health conditions they have can cost consumers even more.
A 3-year study of 200,000 Cigna customers has revealed just how expensive correctable health conditions, such as higher weight, cholesterol, and blood pressure, can be to individuals. Even worse, not knowing what health conditions they have can cost consumers even more.
Cigna found that individuals who have not undergone a biometric screening have higher health costs. For instance, patients who have not had a biometric screening of blood pressure values have health costs that are $2064 higher per year than people who verify their blood pressure is lower than 140/90.
“In too many cases our health and costs are getting worse, but it’s also in our power to change that,” Cigna Chief Nursing Officer Mary Picerno said in a statement. “Yes, we have to work hard, and have to do things we haven’t done before, but still, we can change it. And when we do, there can be financial rewards, along with the ultimate reward of better health.”
Overall, annual out-of-pocket costs increases $492 with a body mass index (BMI) of more than 30 and more than $353 with a cholesterol reading of more than 240. In addition, 2 or more chronic conditions indicated by unhealthy BMI, blood pressure, cholesterol, and blood sugar, increases annual out-of-pocket costs by almost $1300 and total healthcare costs by nearly $9000 per year.
However, the good news is that Cigna’s study revealed incentive programs play a key role in getting individuals to undergo biometric screenings, engage in healthier behaviors, and improve clinical outcomes and costs. With incentives, biometric screening rates increased from 20% to 55% in 2014. Incentives also increased the probability of meeting biometric targets.
“Employers are increasingly rewarding employees who identify and address their potential health risks, by discounting the employee’s health plan premiums or adding funds to their health spending account to lower their annual out-of-pocket expenses,” Picerno said.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More